American Joint Committee on Cancer (AJCC) staging is increasingly accepted as a prognostic standard for cancer management.
The Commission on Cancer requires approved cancer programs to use AJCC staging for all cancers.
Previous studies document increasing use of AJCC staging by hospitals with cancer programs.
This review examines programmatic and clinical factors affecting AJCC staging completeness.
The data are registry records submitted to the National Cancer Data Base (NCDB) for cases diagnosed during 1993 or, for comparison, 1988.
The mean facility staging rate was 87% in 1993, up from 65% in 1988.
Approximately 64% of facilities staged greater than 90% of their stageable cases ; 3% staged less than 5%. Even facilities with « complete » staging implementation were unable to stage substantial portions of some sites.
Accessibility of tumor and overall prognosis affected the choice between pathologic and clinical staging.
Staging completeness and the mix of pathologic and clinical staging also differed by state of the reporting facility.
AJCC staging use is high among common tumors for which treatment is dependent upon stage of disease.
However, if accurate staging is not expected to affect the treatment or outcome of the case or the overall outcome is poor, staging is less frequently recorded.
Mots-clés Pascal : Tumeur maligne, Homme, Evaluation, Pratique professionnelle, Classification, Stade clinique, Milieu hospitalier, Complétude, Etude comparative, Base donnée, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Malignant tumor, Human, Evaluation, Professional practice, Classification, Clinical stage, Hospital environment, Completeness, Comparative study, Database, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0469727
Code Inist : 002B04A. Création : 10/04/1997.